Compare Bristol-Myers Squibb Co (BMY) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco WilderHill Clean Energy ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $132.45B), while Invesco WilderHill Clean Energy ETF trades at $34.96. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Invesco WilderHill Clean Energy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BMY | PBW | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $46.99 |
52-Week Low | $42.60 | $24.14 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
PBW trades at $34.81, up 3.48% today, with a neutral technical signal and mixed moving averages. The clean energy ETF shows strength amid sector tailwinds from geopolitical tensions and data center demand, though it faces volatility from interest rate sensitivity. A dividend of $0.24 is scheduled for June 2026, but key valuation ratios like P/E and P/S are unavailable in the data.
The outlook hinges on clean energy adoption trends and Federal Reserve policy, with opportunities in global investment shifts but risks from rate cycles and oil price swings. Analyst sentiment is divided, reflecting the ETF's exposure to macroeconomic factors over company-specific fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
